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Abstract: It is well established that currently available inhaled drug formulations are associated
with extremely low lung deposition. Currently available technologies alleviate this low deposition
problem via mixing the drug with inert larger particles, such as lactose monohydrate. Those inert
particles are retained in the inhalation device or impacted in the throat and swallowed, allowing
the smaller drug particles to continue their journey towards the lungs. While this seems like a practical
approach, in some formulations, the ratio between the carrier to drug particles can be as much as 30
to 1. This limitation becomes more critical when treating lung conditions that inherently require large
doses of the drug, such as antibiotics and antivirals that treat lung infections and anticancer drugs.
The focus of this review article is to review the recent advancements in carrier free technologies
that are based on coamorphous solid dispersions and cocrystals that can improve flow properties,
and help with delivering larger doses of the drug to the lungs.
Keywords: cocrystals; coamorphous; solubility; dry powder inhalers; pulmonary drug delivery
1. Introduction
The respiratory tract is susceptible to a range of conditions, such as viral, bacterial
and fungal infections [1], which in turn can result in an exacerbation of other existing
conditions through inflammation [2]. Lower respiratory tract infections which include
bronchitis, tuberculosis and pneumonia, are classed as two of the leading causes of death,
while pneumonia is a leading cause of death in children globally [3]. While inflammation
can affect the entire respiratory system, different pathogens will inhabit different parts of
the respiratory tract. For example, tuberculosis causative microorganism Mycobacterium tu-
berculosis colonises the lungs, deep within, and also inside the lung’s alveolar surfaces [4].
In cystic fibrosis (CF) patients, the bacterium, Pseudomonas aeruginosa, inhabits the conduct-
ing and respiratory zones of the lungs and is associated with recurrent infections. This is
mainly caused by bacterial transformation to the biofilm producing mucoid strain, which
exhibits increased resistance to both antibiotics and natural lung defence mechanisms, such
as phagocytosis.
In addition to respiratory tract infections, lung cancer is a major cause of death. It is es-
timated that 1.6 million people die every year from lung cancer, making it one of the most
fatal cancers [5]. Lung cancer remains difficult to cure using chemotherapy, as evident by
the low long-term survival rate of patients [6]. Apart from the frequent low efficacy, cancer
treatments have been associated with significant side effects. A study that included 449
cancer patients, revealed 86% of patients experienced at least one side effect from cancer
chemotherapy, with 67% having experienced six or more side effects [7]. This calls for the ex-
ploration of new approaches, aimed at reducing the side effects, and in turn, improving
patient tolerance [8], and further improve the quality of care provided to patients.
The pulmonary route has been used to treat different lung conditions, such as asthma
and chronic obstructive pulmonary disease (COPD). Drugs delivered to the lungs are
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typically formulated in low doses; however, there is an increasing clinical need to de-
liver higher doses. For example, when antimicrobials are delivered directly to the lungs,
higher doses ensure optimum lung concentration for tackling the infection [9]. Hence,
a major challenge is to formulate these drugs with efficient deposition, while maximising
the delivered dose. Current technologies are based on formulating the required doses
of the active pharmaceutical ingredient (API) with the addition of excipients (known as
carrier particles) [10]. These carrier particles serve to minimise undesired deposition into
the oropharyngeal region, as well as reducing loss in the inhalation device itself. Among
approaches to deliver larger doses of the drug to the lungs is solid dispersions. These are
molecular mixtures of the drug and a miscible carrier by which properties can be tailored
to achieve optimum outcomes, such as improved solubility [11]. The carrier can be a small
molecule known as a coformer or a polymeric carrier leading to the formation of crystalline
or amorphous dispersions.
Although oral formulations have a more enhanced therapeutic profile when it comes to
treating systemic diseases, inhaled drug formulations are better at targeting lung conditions,
such as infections and cancer. The aim of this review article is to explore the respiratory
route for drug delivery, highlighting its advantages and challenges to deliver larger doses.
While there have been different approaches to maximise the dose that can be delivered,
the focus of this review is on recent advancements in the delivery of particulates pre-
pared as solid dispersions. The use of solid dispersions represents a novel approach to
deliver larger amounts of the drug while maintaining enhanced physicochemical prop-
erties. These physical molecular complexes (i.e., solid dispersions) can be engineered to
modify properties, such as adhesion, aerodynamic diameter and morphology, allowing
enhanced pulmonary drug delivery.
Physiology of the Lungs and Factors Affecting Particles Deposition
The pulmonary alveoli exhibit a large surface area of over 100 m2 and thin walls of
less than 1 µm, allowing fast absorption of drugs into the rich blood supply for systemic
effect [12]. This would be beneficial for a number of drugs as the fast absorption would
result in a more rapid onset of action compared to other administration routes, such
as oral administration. As well as being advantageous for drugs acting both locally
and systemically, it also has reduced systemic side effects that are common with other
administration routes [13]. It is considered a non-invasive form of drug administration
and often require lower doses compared with other systemic drug delivery routes [14].
The local administration also avoids first pass liver metabolism, which is detrimental for
some drugs. Thus, the pulmonary route may be favoured over other parenteral routes,
or when absorption via the gastrointestinal (GI) tract is inappropriate or ineffective [12,15].
The respiratory system comprise 23 generations (G0–G23) which have varying sizes,
structures and functions [16]. Each generation splits into two smaller daughter branches
to give the next generation. Altogether, these generations are divided into two zones:
Conducting and respiratory. The conducting zone includes the structures from the trachea
to the bronchioles from G0 to G16. The main role of the conducting zone is to carry the air
into the lungs. The respiratory zone includes structures from the respiratory bronchioles
to the alveolar ducts and alveoli from G17 to G23. This zone contains functional tissues
where gaseous exchange occurs [17].
As a result of the varying size and structure of the lungs, inhaled particle size affects
how deep into the lungs the drug and excipients can penetrate. For example, particles with
a mass median aerodynamic diameter (MMAD) of 10 µm or larger tend to be deposited
in the oropharyngeal region, whereas smaller particles with an MMAD of less than 3 µm can
penetrate much deeper through the lungs into the alveoli [18]. MMAD is a measurement
used to define the size of aerosol particles. The aerodynamic diameter of a particle relates
to a sphere with the same density as water (1 g/cm3) which settles at the same velocity
as the particle of interest in still air [19]. Using the mass median value, the aerosol size
distribution is divided in half [20].
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Particles intended for pulmonary drug delivery are categorised according to their
size. The ideal particle size for inhalation is said to be <5 µm [21], with <3 µm having
an 80% chance of reaching the lower airways and 50–60% chance of reaching the alveolar
regions [22]. Particles > 5 µm are identified as coarse particles; fine particles range from
0.1–5 µm, and ultrafine particles are <0.1 µm. A monodisperse aerosol is said to be highly
desirable for maximum deposition and specific targeting in the lungs [23]. However, there
have been reports showing minimum differences in deposition between polydisperse and
monodisperse aerosols [24]. The deposition of inhaled particles within the regions of
the lungs is dependent on a number of physiological and pharmaceutical factors, such as
particle shape, particle size, surface morphology, the breathing rate of the patient, lung
volume and health condition of the patient. The physicochemical factors that affect particles
deposition in the respiratory system are shown in Table 1. Particle deposition can occur
through the following mechanisms: sedimentation, impaction and diffusion. Diffusion
is a fundamental mechanism of particle deposition for particles < 0.5 µm. The process is
influenced by Brownian motion—in other words, motion increases with decreasing particle
size and particles move from a higher concentration to a lower concentration leading to
the deposition upon contact with the airway walls. This mechanism heavily influences
deposition in the lower regions of the lungs and the alveoli. Gravitational sedimentation
can happen at a later region, typically within the tracheobronchial region (approximately
the last six generations), as a result of the relatively low air velocity within this region [25].
In fact, as the residence time is longer, a combination of both sedimentation and free
diffusion can occur. It is vital for drug absorption to occur, that the particles are deposited
before exhalation takes place. Typical size depends on the aerodynamic diameter, which
is approximately above 0.5 µm for sedimentation and below that for diffusion [26,27].
The bigger the particle and the lower the airflow rate, the faster the sedimentation in which
inertial impaction plays a significant role for particles > 5 µm [28].
Table 1. Physicochemical factors to be considered when designing inhaled formulations. Each parameter















Note—* Factors specifically affecting aerosolisation.
2. The Necessity to Deliver Larger Doses to Treat Lung Infections and Cancer
There are a variety of inhaled products for the treatment of conditions affecting the res-
piratory system (Table 2). As can be seen in Table 2, the maximum dose that has been
successfully formulated for inhalation, thus far, is colistimethate sodium, with doses rang-
ing from 80 to 125 mg, formulated as inhalation powder. Many of the higher inhalable
doses are administered via the use of nebulisers, which may require guidance and can
also be complicated for patients to use [32]. Desgrouas and Ehrmann reviewed the avail-
able evidence and called for developing inhaled antibiotics, especially for mechanically
ventilated patients [33]. However, the majority of inhalable drug formulations are avail-
able in the dose range of micrograms and are indicated for conditions, such as asthma
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and COPD. In addition, there is a limited number of inhaled medications available as
combinations, which are again mostly limited for use in asthma and COPD.
Table 2. Examples of currently available inhaled products in the market.
Drug Quantity of API per Dose Indication Ref
Salbutamol 100–200 µg Asthma [34]
Fluticasone propionate 50–500 µg Prophylaxis of asthma [35]
Colistimethate sodium 80–125 mg Treatment of pneumonia [36]
Tiotropium 10–18 µg Maintenance of COPD [37]
Nedocromil sodium 2 mg Prophylaxis of asthma [38]
Zanamivir 5 mg Treatment of influenza [39]
Mannitol 5–40 mg Treatment of cystic fibrosis as add-on therapy tostandard care [40]
Budesonide with formoterol 100–400 µg with 4.5–12 µg Maintenance of asthma [41]
Ciclesonide 80–160 µg Prophylaxis of asthma [42]
There are two major lung conditions that require high doses of medications, these
being infections and malignancy. For lung infections, the causative bacteria and viruses
can be found throughout the different structures of the lungs, which will alter the efficacy
of treatment. The conducting zone of the respiratory system, which consists of the tra-
chea, bronchi and bronchioles, plays a role in trapping microbes in mucus produced by
goblet cells. The mucus is then transported by ciliated cells located on the epithelium
to the oropharynx, where the mucus is either swallowed or removed via coughing [43].
However, in cases where the microbes go on to develop into infections, it is important to
determine the specific site in the lungs where the infection has developed to effectively
target and deliver the drug directly to the causative microbes. Table 3 lists common loci of
prevalent microorganisms within the respiratory tract noting that several pathogens found
in the respiratory tract are associated with the development of biofilms.
Upper respiratory tract infections typically occur in the conducting zone, examples
of which include common cold, sinusitis and pharyngitis, whereas lower respiratory
tract infections happen in the respiratory zone and include pneumonia and bronchitis.
In addition, some microorganisms, such as Haemophilus influenzae, that are normally found
in the conducting zone can go on to migrate to the respiratory zone, subsequently causing
lower respiratory tract infections [44]. Some studies suggest that the conducting zone of
the respiratory tract is the more common zone where bacteria and viruses are contained
during infections. One study found that for Pseudomonas aeruginosa biofilms in cystic
fibrosis patients, the majority of the bacteria were present in the conducting zone, which
acted as a reservoir for the bacteria to multiply and form biofilms [45]. Consequently, it is
important for inhaled formulations of antibacterials and antivirals to reach and deposit
in the conducting zone of the respiratory tract to effectively treat the infections. With
the ability to locally deliver antimicrobial drugs for treatment, there could also be a further
advantage of reducing antimicrobial resistance. With oral and intravenous administration,
there is a risk of an accumulation in infection-free sites, leading to the development of
antimicrobial resistance. In addition, a number of antimicrobials, such as tobramycin,
can be toxic when given in repeated high doses systemically, which can occur when
antimicrobials are prescribed for recurrent infections [46]. Hence, utilising local drug
delivery directly into the lungs could reduce the risk of toxicity.
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Table 3. Location of infections causative microorganisms within the respiratory tract.
Organism Type Location/Generation Reference
Bacteria
Pseudomonas aeruginosa Non-mucoid strain located mainly in the conduction airwaysMucoid strain present throughout the respiratory zone [47]







Alveolar type 2 cells
[4]
[2]
Fungi Aspergillus spp. Terminal bronchioles, Terminal airwaysGeneration 16–23 [49]
Viruses Herpes Simplex Virus Oropharynx–Generation 0 [48]
Similar to infectious conditions, lung cancer is another serious condition that requires
large doses of drugs for treatment. Current survival rates for all stages of lung cancer
include 40% of patients surviving for one year or more after diagnosis, 15% of patients
surviving for five years or more after diagnosis and only 10% of patients surviving for
10 years or more after diagnosis [50]. The nature of lung cancer suggests that it is more
effectively treated by direct delivery to the lungs. Sardeli et al., suggested the need to use
inhaled immunotherapy as opposed to intravenous administration to avoid systemic side
effects and achieve a localised effect [51]. Hence, pulmonary drug delivery provides a novel
opportunity to avoid unwanted drug distribution and could achieve maximum deposition
of the drug at the site of action. As such, there is the potential for higher concentrations of
the drugs to reach the lungs compared with oral and intravenous administration. Lung
cancer cells are prone to rapidly developing resistance to anticancer drugs, so higher doses
are given to combat this challenge [52]. When administered systemically, chemotherapy
drugs can cause toxic side effects affecting healthy organs, especially when administering
large doses, which may be prevented by local administration of the drugs [53]. By targeting
the lungs directly, this also means there is potential for an accumulation of the drug to build
up in the tumour cells, rather than in the kidneys, liver and spleen, which is observed with
systemic drug use [54]. This has the potential to beneficially impact patients’ treatment and
increase the likelihood of remission and survival.
3. Challenges Associated with Drug Delivery to the Lungs
Whilst pulmonary drug delivery has its advantages, to ensure advantageous depo-
sition in the lungs, drug particles must be within the optimum size for lung deposition
(Table 4 and Figure 1). If the particle size is relatively large, the deposition will occur
in the larynx causing irritation, and if the particle size is relatively small, the particles will
be immediately exhaled from the lungs and will not be deposited [55]. It is important to
note that drug particles should be deposited in the lungs in a high enough proportion
for the API to be absorbed and produce a therapeutic effect. Unsurprisingly, it has been
shown that higher drug deposition in the lungs leads to enhanced clinical benefits [56].
As mentioned above, a common approach to improve the flow properties of powder for
inhalation is to use carrier particles (such as lactose monohydrate). This is based on com-
bining the drug with the larger lactose particles, which strip from the drug particles inside
the device in response to the high velocity created by inhalation [57,58]. Any escaped
lactose will deposit in the throat, leaving the drug particles to carry on with their journey
towards the alveoli. Hence, the main challenge would be to deliver high doses of the API
without significant loss in the oropharynx region. Another challenge is that inhalation
devices do not have the capacity to accommodate high masses of powders [59].
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As shown by the data collated and presented in Table 4, two different studies used
a combination of beclomethasone dipropionate with formoterol labelled with technetium-
99. The first dissolved the particles in hydrofluoroalkane to give an MMAD of 1.3 µm via
pressurised metered-dose inhaler (pMDI) [60], the second delivered the solid particles with
MMAD of 1.5 µm via a NEXThaler® dry powder inhaler (DPI) [61]. The lung deposition
for the pMDI was 34.08% (standard deviation (SD) = 9.3%), and the DPI had a lung
deposition of 55.2% (SD = 3.7%). This shows that even though the same APIs were used,
and the particle sizes were similar, the way that the API is formulated plays a significant
role in the lung deposition of the particles. It is apparent that the type of the API has
an effect by comparing the lung deposition of albuterol and beclomethasone dipropionate
with formoterol in the pMDI considered previously [62]. They both have an MMAD of
1.5 µm, are labelled with technium-99 and are administered using an pMDI; however,
the lung deposition of albuterol was 56.3% (SD = 9.2%), which is considerably higher than
the beclomethasone, which has a lung deposition of 34.08% (SD = 9.3%). This suggests that
API type and formulation must also be carefully considered when formulating drugs for
pulmonary drug delivery.
Furthermore, Table 4 shows that within the same administration device, the prepara-
tion method of the particle has an impact on the deposition within the lungs. One study
compared two suspensions of beclomethasone dipropionate labelled with technetium-99
in a metered-dose inhaler, by which the first formulation was dissolved in hydrofluo-
roalkane, and the other was dissolved in chlorofluorocarbon [63], it demonstrated that
the different preparation methods led to a difference in both MMAD and lung deposition.
Therefore, this suggests that the type of excipients used must be carefully considered for
optimum lung deposition.
Table 4. MMAD, lung deposition and preparation method of different inhaled APIs.
API MMAD (µm) Lung Deposition (%) Preparation of API Ref
Formoterol 0.8 31 ± 11
Labelled with technetium-99 and
dissolved in hydrofluoroalkane
(HFA) in an pMDI
[64]
Beclomethasone dipropionate 0.9 53 ± 7 Labelled with technetium-99 anddissolved in HFA in an pMDI
[63]
Fluticasone propionate 2 12 ± 7 Labelled with technetium-99 and
dissolved in chlorofluorocarbon
(CFC) in an pMDIBeclomethasone dipropionate 3.5 4 ± 11
Albuterol (salbutamol)
1.5 56.3 ± 9.2
Labelled with technetium-99
in an pMDI
[62]3 51 ± 8.9
6 46 ± 13.6
Beclomethasone dipropionate
and formoterol 1.3 34.08 ± 9.3
Labelled with technetium-99 and
dissolved in HFA in a pMDI [60]
Ciclesonide 1 52 ± 11 Labelled with technetium-99 anddissolved in HFA in a pMDI [65]
Beclomethasone dipropionate
and formoterol fumarate 1.5 55.2 ± 3.7
Labelled with technetium-99
in a NEXThaler® DPI [61]
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4. Impact of Drug Delivery Devices on the Extent of Pulmonary Drug Delivery
There are currently three major categories of delivery devices that are used for in-
halation th r py: p essurised metered-dose inhalers (pMDIs), nebulis rs and d y powder
inhalers (DPIs). pMDIs are wid ly available, portable inhalers designed to rel ases a spe-
cific dose of the drug, following depression of an actuator, which the patient then inhales
in a single inspirati n or via a spacer device. Studies have found that many patients
have difficulty in using these devices, due to the required coordination of pressing down
on the actuator and inhaling the resultant mist simultaneously [66]. If patients do not
have the required coordination to self-administer their medication using a pMDI, some of
the drug is deposited in the mouth and at the back of the throat. As a result, less of the API
will be inhaled than intended, so the correct dose will not be administered. This could
potentially result in substandard treatment, leading to exacerbation or worsening of a pa-
tient’s condition. pMDIs are formulated as a suspension or solution with one or more
APIs along with a propellant. The propellant is used to generate the pressure required
to form micron-scaled droplets for inhalation [67]. Furthermore, pMDIs deposit less of
the drug into the lungs, due to the high particle exit velocity with the actuations [68].
This means that it is more difficult to formulate higher drug doses for use with this type of
inhaler device.
DPIs are portable inhalers that operate by breath actuation, thus removing the need
for coordination of inhalation with actuation required for pMDIs. Breath actuation involves
the powder being released from the inhaler when the patient inhales with enough force,
known as inspiratory flow. The inhalers are formulated to contain powder forms of drugs,
and this solid-state gives the drug improved stability compared to pMDIs formulations [67].
The use of powders also allows for greater potential when formulating higher dose med-
ications. Dry powder inhalers are available in three types: single-unit dose, multi-dose
reservoir and multi-unit dose. The powder is stored in either capsules or sealed blisters
that are broken during actuation. In general, patients tend to find that multi-dose DPIs
are preferable to single-unit dose DPIs, due to the convenience of not having to replace
the capsule or blisters with every use of the inhaler.
Nebulisers are less popular inhalation devices compared to the other two devices and
are available in two forms. The most common nebuliser is the jet nebuliser, which works
by passing a liquid formulation along with compressed air through a narrow tube into
a wide chamber, which causes a reduction in pressure. This reduction in pressure then
forms micron-sized droplets, which can then be inhaled. The alternative type of nebuliser
is the ultrasonic nebuliser, which breaks down the solution of the drug into inhalable
droplets by piezoelectric vibrations [68]. Both types of nebulisers require a face mask or
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mouthpiece, which are bulkier and less portable than the other two devices, and therefore,
less convenient for frequent and repeated use [69]. The way nebulisers are formulated are
unsuitable for some drugs, particularly for drugs that are unstable when in solution [70].
Nebulisers also take longer to administer the drug when compared to other drug delivery
devices, due to the time taken for the drug to pass through the chamber into the mouthpiece
or mask, and with inhalation over a prolonged period. The use of nebulisers can also result
in the administration of less precise doses as there can be deposition of the API particles
in the chamber and mouthpiece or face mask. In general, nebulisers tend to be used by
patients who cannot use the other devices, due to difficulties with coordination associated
with pMDIs and/or the inability to produce adequate inspiratory flow associated with
DPIs. The main patient groups these affect are young children, elderly populations, patients
with COPD and patients with CF [71].
There is a limited number of licensed inhaled antimicrobials that are only available
for patients suffering from recurrent infections as in CF (Table 5). Other antibiotics, such
as gentamicin and amikacin, can be nebulised for pulmonary drug delivery by using
the solution for injection if required; however, these cases are for unlicensed use in CF
patients only and not for use for respiratory infections [72]. As can be seen in Table 5,
nebuliser solutions and inhalation powders can be used to formulate higher doses of drugs,
and hence, these are the devices currently used on the market. Tobramycin, colistimethate
sodium and zanamivir are all available as dry powders for inhalation. Tobramycin inhala-
tion powder is produced via an oil-in-water emulsion-based spray-drying process [69],
and each particle consists of an amorphous tobramycin sulphate, and a gel-phase phospho-
lipid 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC). Tobramycin inhalation powder
comes in a device known as a TOBI® Podhaler®, which consists of the engineered dry
powder, the hard capsule, which is the primary packaging of the powder, and the device to
administer the powder [70]. Other excipients used in the capsules include calcium chloride,
which is used to stabilise the emulsion droplets during the spray drying and sulphuric
acid for pH adjustment [71,73]. Each inhalation delivers 28 mg of tobramycin from the cap-
sule to the lungs; however, four capsules are required for each dose, and therefore, eight
inhalations per day. Colistimethate sodium is an inactive prodrug of colistin (polymyxin
E), and is formulated as such to reduce the toxicity, typically nephrotoxicity, that is often
experienced by patients when taking colistin. It is formulated to be administered using
a Turbospin® inhaler, under the brand name Colobreathe® [74]. The powder is micronised
and filled in polyethylene glycol (PEG)-gelatin hard capsules, which also contain purified
water and sodium lauryl sulphate as excipients [75,76]. Zanamivir is an antiviral drug
used for the treatment and prevention of influenza. It is formulated under the brand
name Relenza® for its inhalation powder, and is produced via air-jet milling to contain 5
mg of zanamivir and 20 mg of lactose monohydrate particles as carrier particles in each
double-foil blister [77].
Table 5. Licensed inhaled antibacterials currently available on the market.
Antibacterial Drug Form Available Strength Ref
Tobramycin
Nebuliser liquid 300 mg/5 mL, 300 mg/4 mL, 170 mg/1.7 mL
[78]
Inhalation powder 28 mg (1 dose = 4 × 28 mg inhalations)
Colistimethate sodium
Inhalation powder 1,662,500 IU ≈ 125 mg
[79,80]
Powder for nebuliser solution 1,000,000 IU ≈ 80 mg
Aztreonam Powder and solvent for nebuliser solution 75 mg [81]
5. Pulmonary Drug Delivery Using Carrier Free Technology
Large carrier particles, such as alpha-lactose monohydrate, are added to the API to
form an inhaled powder with enhanced formulation properties. These properties include
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the flowability and aerosol dispersion of the powder to maximise the number of API parti-
cles reaching the site of action. Lactose is available in a variety of grades for inhalation, with
median diameters ranging from <5 µm to 250 µm [82]. During formulation, micronised
API particles with an MMAD of between 1 µm and 5 µm are attached to the surface of these
much larger carrier particles. Physical interactions hold the API in place, which prevents
agglomeration of micronised API, due to cohesive forces. On inhalation, API is detached
from the carrier and aerosolised, due to force exerted by the inhaler design in the form of
friction, inertia and drag [83]. By retaining micronised API particle size, maximum disper-
sion of powder into the lungs is seen, due to increased aerosolisation [84]. This influences
the drug administration in addition to preventing problems during the manufacturing
process of the powder [85].
Carrier-based DPIs are the most prevalent formulation of DPIs and tend to be used to
deliver relatively higher doses of API compared to pMDIs. However, certain mass ratios of
API to carrier particles must be maintained to prevent agglomeration, as for example these
can vary depending on the type of the drug, ranging from 1:2 to 1:4 in some cases [86].
For example, Relenza® requires a 25 mg powder to be inhaled so that to deliver 5 mg of
zanamivir (i.e., a mass ratio of 1:5). These ratios create a maximum practical dose that
can be delivered to the lungs through dry powder inhalation, making high dose delivery
even more challenging. Even with carrier particles enhancing aerosolisation, deposition
in the lungs is still relatively low, and as a result, the amount of API to reach the site of
action is low. Fine particle fraction (FPF) refers to the fraction of particles with a size smaller
than the respirable size divided by the total emitted dose of the inhaled API [87]. DPIs
that do not contain carrier particles, therefore, have greater potential for delivering higher
doses to the lungs.
Carrier free DPIs are a new-generation system that use special excipients and technolo-
gies, such as crystal engineering, to formulate micronised API particles whilst addressing
the limitations explained above. These methods can increase the amount of lung depo-
sition, with some formulations reporting FPF values of 63% [88]. One of the benefits of
developing carrier free DPI formulations is that there can be an increased mass of API
without having to retain large masses of the carrier particles. Therefore, this can max-
imise the dose available in each inhalation through maximising the amount of API that
is deposited in the lungs. There are several dry powder formulations that have been or
are currently being investigated to produce carrier free dry powder inhalers, as shown
below in Table 6. As can be seen, different doses have been tested with some formulations
delivering doses up to 50 mg, as displayed in Figure 2.
Many different methods have been used to develop dry powders for inhalation, also
shown in Table 6, and each method produces variation to yield, cost of production and
manufacture time. This data shows the difference in the size of the doses able to be
formulated in DPIs for inhalation, compared to current doses available for inhalation
(Figure 2). This also suggests that the use of carrier free inhalation technology can play
a key factor in addressing the challenge of increasing doses of drugs for pulmonary drug
delivery. Also noted is the wide range of drug classes that are being considered with regards
to delivery via dry powder inhalation, including non-steroidal anti-inflammatory drugs
(NSAIDs, i.e., ibuprofen and indomethacin), antimicrobials (i.e., tobramycin and netilmicin),
antihistamines (i.e., ketotifen), and phosphodiesterase type 5 inhibitors (i.e., sildenafil).
It was also noted that for many antimicrobials, there is the possibility of creating drug
combinations within the same device—a useful tool for patients who require complex
antimicrobial treatment.
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Table 6. Carrier free DPIs and the technology used to produce the powders.
API Dose in Capsule Conditions Used Ref
Indomethacin 3 mg Spray drying an aqueous-based feed to form microparticles [89]
Ethionamide + moxifloxacin 20 mg Spray drying using a mini spray dryer [90]
Ketotifen 20 mg Spray drying with different solvents (water, ethanol andwater-ethanol mix) [91]
Sildenafil 5 mg Spray drying using a mini spray dryer [92]
Ibuprofen 50 mg Air-jet milling to produce micronised samples [93]
Sodium cromoglycate 20 mg Pelletised [94]
Tobramycin + clarithromycin 22.72 mg tobramycin, 2.27 mgclarithromycin Spray drying [95]
Salbutamol sulphate 5.1–7.1 mg Gas-phase coating method to produce L-leucine coated powders [96]
Tranexamic acid 38 mg Spray drying [97]
Roflumilast 20 mg Spray drying with hydroxypropyl-β-cyclodextrin [98]
Tobramycin 28 mg Micronised using a Labomill jet milling system [99]
Meloxicam potassium 1.3 mg Cospray drying [100]
Ciprofloxacin + colistin 10 mg Cospray drying [101]
Netilmicin 30 mg Cospray drying [102]
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6. Pulmonary Drug Delivery on the Nanoscale
Nanoparticulate formulations maintain nanoscale particles of the drug through en-
capsulation within inhalable size particles to prevent aggregation and ensure deposition
of nanoparticles in the lung. There are several particle engineering methods to achieve
nanoparticle formulation, such as the use of liposomes, solid lipids and polymers, which
have been reviewed elsewhere [103–105]. It is common for these formulations to be stored
as suspensions then delivered to the lung through a nebuliser; however, carrier free, dry
powder nanoparticle formulations are also being developed.
Zhu et al., described the formulation of poorly soluble ivacaftor (Iva) as bovine serum
albumin nanoparticles, which were then spray freeze-dried with different ratios of soluble
colistin (Co) matrix and L-leucine [106]. All subsequent formulations showed high emitted
dose following inhalation for both APIs (>90%); however, a range of FPF values (%) were
seen corresponding to initial solid content in the formulations. Dissolution rates of the best
performing nanoformulation and a jet-milled physical mixture of Iva and Co were then
compared. After 3 h, the nanoformulation showed three times greater dissolution of
Iva compared to the physical mixture control, with the concentration of Iva dissolved
equivalent to highly soluble Co. Enhanced dissolution of Iva was attributed to the albumin
maintaining Iva nanoscale particle size and amorphous form. The use of Co as a water-
soluble matrix both enhanced the dispersion of Iva nanoparticles, as well as broadening
the formulation clinical scope for patients with cystic fibrosis.
Doxorubicin nanoparticles (DNPs) were formulated as a colloid through emulsion
polymerisation then spray freeze-dried with lactose to form particles of inhalable
size [107,108]. DNPs showed increased survival rates compared to IV doxorubicin controls
(including IV DNPs) in a rat model and much lower cardiotoxicity compared to doxorubicin
DPI control. DNPs were also formulated with sodium carbonate to enhance the release of
doxorubicin from the formulation. When inhaled, the effervescent formulations showed
increased survival rates compared to DNP controls showing the importance of an active
release mechanism from the formulation. In a slightly different approach, often utilising
nanoscale dimensions to enhance inhalation properties, the use of porous particles has
been investigated and was shown to improve efficacy of inhalation [109–111].
7. The Design of Carrier Free Formulations Using Coamorphous Solid Dispersions
(CACDs)
Most solid APIs exist in a crystalline state held together by strong intermolecular bonds,
and therefore, display good stability profiles (Figure 3). However, the crystalline state often
shows poor solubility, due to the high energy required to break the crystalline lattice which
creates a major problem for developing new APIs [112,113]. There has been much interest
in the process of ‘drug amorphisation’, to address poor solubility, which involves the conver-
sion from a crystalline state to an amorphous solid state. The amorphous solid state offers
an improved solubility and dissolution rates as a result of possessing higher entropy [114–116].
The advantages associated with higher energy forms are often negated, due to recrystallisation
to a more thermodynamically stable form during processing and storage [117–119]. This can
limit applications, and so the production and maintenance of amorphous drugs with adequate
stability remain a challenge. Formulation strategies based on solid molecular dispersions
are being explored, including polymeric amorphous solid dispersions (PASDs), and more
recently, coamorphous solid dispersions (CASDs).
PASDs incorporate low API loading within a compatible polymer to maintain the sol-
ubility advantage of amorphous systems through the formation of strong intermolecular
attractions [120]. Examples of PASDs applications are seen in the combination of paclitaxel
and polyvinylpyrrolidone (PVP), ritonavir and PVP, ciprofloxacin and polyvinyl alco-
hol [121–123]. However, the main limitation of this approach is the low level of API loading
within the formulation, requiring increased dosing. In addition, many polymeric carriers
are hygroscopic, which can lead to API recrystallisation while in some cases polymers
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can be unsuccessful in maintaining a good stability profile [123]. The applications and
limitations of PASDs have been highlighted in a number of reviews [124–126].
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CASDs are a relatively new formulation approach through which the crystalline drug
is amorphised thermally or mechanically and stabilised with a small molecular weight
coformer. These systems are often stabilised through strong intermolecular hydrogen bond-
ing and exhibit apparent stability, due to an increased glass transition temperature [124].
Glass transition temperature refers to the temperature at which below, the system exists
in an unstable glassy state and above, the system exists in a rubbery state [125]. CASDs
can be obtained through different preparation methods, such as freeze drying, quench
cooling, milling and solvent evaporation methods [126,127]. Milling is an example of me-
chanical amorphisation where a direct mechanical impact on the drug causes a disturbance
in the crystalline structure, forming an amorphous state. Quench cooling and solvent evap-
oration are examples of thermal amorphisation where a crystalline solid state is prevented
from reforming, due to molecular level interactions. Here, the drug is either in a liquid
state following melting or dissolved to form a solution then rapidly cooled, or solvent
removed rapidly. CASDs are believed to be able to provide an increase in drug kinetic
solubility thanks to the high energy of the amorphous state driving faster dissolution [128].
In addition, improved physical stability is offered through an increase in the glass transition
temperature (Tg) and the presence of intermolecular interactions between the API and
coformer, as reported by several research papers [124,129]. CASDs are said to reduce hygro-
scopicity, as API hydrogen bondi g regions are strongly bound to the coformer. Therefore,
hydroge bonding with water is less favourabl , which hel s to maintain stability and
particle integrity.
CASDs provide the opportunity for many types of formulations, such as drug-
excipi and drug-drug combina ions, and many have been report d as being successful.
An example of a drug-drug combination is the spray drying of colisti with azithromycin
to treat infections caused by multi-drug resistant b ct ria [130]. A study conducted by
Wang et al., showed an enhanc d solubility profile b tween tw APIs with low aqueous
solubil ty: lacidipine and spironolactone [131]. Many o her drug-excipient combinations
are listed in T ble 7, by which commonly used coformers in CASDs for pulmonary drug
deliv ry include mannit l, sugar and amino acids, such as leucine [132,133].
The spray dryin technique is based on solv t evaporation which u es the processes
f liquid atomisation, gas/droplet mixi g and drying to create micr particles [134]. Fir t,
a liquid feed consisting of mixed components, typically pure API, excipient and a common
solvent, is converted into smaller droplets via atomisation. Next, the droplets are sprayed
downwards into a vertical drying chamber exposed to air or nitrogen at a temperature
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higher than the solvent boiling point [135]. Within this drying chamber, the droplets rapidly
shrink in size to produce dry microparticles.
Through spray drying, aspects of particle morphology, such as shape, size and surface
properties, can be highly controlled, which deems the technique appropriate for formulating
inhalation powders. Many papers have controlled particle morphology through variations
to the inlet temperature, the spray nozzle diameter and properties of the feed solution,
such as concentration and viscosity [136]. The inlet temperature (also known as the drying
temperature) and the feed rate are parameters of high importance as they control the rate of
evaporation and drying load, which determine particle properties and product yield [137].
It is common to see outlet temperatures ranging from 70 ◦C to 105 ◦C with inlet temperatures
ranging from 100 ◦C to 210 ◦C. A faster drying rate could lead to a higher product yield,
as there are fewer particles adhering to the chamber walls, which may also implicate that
solvent evaporation is not complete. The spray drying process is highly applicable for large
scale manufacture, where the integrity of formulation is retained despite ‘upscaling’ [138].
Altogether, spray drying offers a great opportunity to incorporate a number of excipients into
one formulation whilst improving the physical stability of the particles.
Table 7. Application of coamorphous solid dispersions prepared using different preparation methods. The inclusion of
PASD of ciprofloxacin was shown to identify the apparent benefits of polymeric solid dispersions compared to coamorphous
solid dispersions.
API Prime Excipient Preparation Method Fine Particle Fraction (FPF) (%) Ref
Cyclosporin A (CsA) Lactose, methylcelluloseand erythritol
Jet-milling and
freeze drying 54 [139]
Ciprofloxacin Polyvinyl alcohol PVA Spray drying 25 ± 2.1 after 6 months [121]
Ciprofloxacin No excipient Spray drying 67.35 ± 1.1 after 6 months [121]
Ciprofloxacin Leucine Spray drying 79.78 ± 1.2 after 6 months [121]
Ciprofloxacin Hydroxypropyl-beta-cyclodextrin Spray drying 36.32 ± 1.3 after 6 months [121]
Colistin No excipient Spray drying 43.8 ± 4.6% [140]
Colistin No excipient Jet milling 28.4 ± 6.7 % [140]
Colistin L-leucine Spray drying 43.8 ± 4.6% (no difference fromSpray dried alone) [140]
Ciprofloxacin No excipient Spray drying 28.0 ± 3.2% [141]
Ciprofloxacin Lactose, sucrose,trehalose, L-leucine Spray drying
Lactose (43.5 ± 3.3%), sucrose
(44.0 ± 4.3%), trehalose (44.0 ±
1.9%), L-leucine (73.5 ± 7.1%)
[141]
Thymopentin Lactose/mannitol,Leucine, poloxamer 188 Spray drying 44.8%, 45.6%, 44.9%, 43.8% [142]
CsA Inulin Spray freeze drying >50 [143]
Tacrolimus Mannitol Thin-film freeze-drying 83.3 [144]
Tacrolimus Raffinose Thin-film freeze-drying 69.2 [145]
Tacrolimus Lactose Thin-film freeze-drying 68.7 [145]
8. Examples of Coformers as Components of CAMs
L-leucine has been widely used in many studies to improve the aerosolisation proper-
ties of particles, due to its antihygroscopic effect and its ability to generate coarse particles,
following surface enrichment. Momin et al., formulated spray dried kanamycin with
various concentrations of L-leucine, showing the 5% L-leucine formulation to have the best
improvement in aerosolisation properties [146]. Likewise, significant increases in aerosoli-
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sation properties were recorded for the other ratios of L-leucine. Other papers also reported
L-leucine as a well-rounded excipient for improving the aerosolisation properties of pow-
der particles. Interestingly Mangal et al., formulated spray dried azithromycin with various
concentrations of L-leucine yet reported no significant change to powder morphology or
FPF (p > 0.05) [132]. In addition, there was no significant increase seen in the percentage
emitted dose (p > 0.05); however, an increased in vitro dissolution rate was reported. A lack
of change to FPF and emitted dose can be explained when considering particle surface
morphology and composition. It is believed that the more corrugated a particle surface is,
the greater the resulting aerosolisation properties. This process is attributed to the success
of L-leucine in improving aerosolisation. Chen et al., reported how changes to the composi-
tion of PASDs result in differences to the surface composition of particles, and therefore,
flowability and aggregation [136]. Perhaps the surface enrichment of azithromycin with
L-leucine for this formulation was poor, resulting in little change to particle surface mor-
phology when compared to the control. When using L-leucine as a coformer, it is important
that drying causes the distribution to the outer regions of droplets, causing recrystallisation
of L-leucine on the particle surface, creating a corrugated effect [147]. This concept has
also been documented by McShane et al. [138]. The impact of spray drying conditions
on particles morphologies was recently highlighted in a different study by which spray
dried coamorphous ciprofloxacin tartrate salt was shown to exhibit improved properties
compared to ciprofloxacin alone [148].
The distribution of the components within the droplet during spray drying is said
to be dependent on physicochemical properties of the components, such as solubility,
the diffusivity of components and hydrophobicity [149]. These properties ultimately result
in the final composition of the surface of spray dried particles. In the example mentioned
above of azithromycin with L-leucine, the solubility of azithromycin is very low, and it likely
had an impact on the distribution of L-leucine within the CASD. Li et al., conducted in vitro
study to assess deposition, by which, spray drying azithromycin with mannitol resulted
in low FPF values ranging between 38–42% [150]. Signifying the impact of preparation
method and locality of excipients, Padhi et al., suggested that by increasing the ratio of
L-leucine may improve surface enrichment, which would result in a substantial increase
in the FPF [151]. In a different study, it was proposed that the presence of hydrophobic
azithromycin helps to control humidity to prevent reduction in FPF [130].
Hassan et al., suggested that surface enrichment of spray dried materials is dependent
on solvent evaporation rate and diffusion coefficients of the solutes [152]. Based on com-
putational fluid dynamics, it was shown that the maximum rate of solvent evaporation
proportionally affected MMAD [153]. It is believed the flow of the solute equates to that of
the solvent; therefore, the movement of solute within a droplet is highly linked to solvent
flow. Lower evaporation rates have a more significant impact on redistribution to droplet
surface for solutes with high diffusion coefficients [149,152]. Shetty et al., when using water
as a solvent, concluded that a low inlet temperature (<120 ◦C) was not considered, due
to the possibility of it not being sufficient for drying [141]. Chen et al., also documented
lower surface enrichment occurring, due to a reduction in the inlet temperature [136].
It is believed that the inlet temperature influences the particle shape, as well as surface en-
richment. The inlet temperature indirectly affects the outlet temperature, and a lower outlet
temperature is believed to result in a more spherical particle shape, which is detrimental to
FPF [154,155].
Benke et al., reported spray dried meloxicam potassium (MXLspd) that was compared
to the carrier-based meloxicam and lactose monohydrate InhaLac® (µMXL + IH70) [21].
As expected MXLspd showed an improvement in FPF < 5 µm (59.47%) compared to µMXL
+ IH70 with an FPF < 5 µm (24.99%). In addition, µMXL + IH70 had an MMAD of 7.18
µm, therefore unfavourable for pulmonary drug delivery. When assessing the impact of
humidity on FPF, authors observed a significant decline (p < 0.0001) observed in the FPF
(<4.9 µm) between cospray dried ciprofloxacin with lactose when stored at 20% RH and
50% RH after 10 days. This may be due to the caking observed, which led to larger powder
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particles formed. Similar observations were reported by Guenette et al., which showed that
larger lactose particles led to reduced flow properties [156]. The larger particle size may
have occurred, due to particle agglomeration when stored at a higher RH. These examples
highlight that for highly aerosolised powder, it is necessary to maintain the stability of
spray dried CASDs when hygroscopic coformers are used. This is because of the presence
of the excipient such as L-leucine, which has been reported to combat moisture-related
stability issues, due to its hydrophobic nature [157]. Part of the reason why CASDs
are successful is that the coformer changes from being a passive carrier to an essential
constituent in the formulation [138].
In a separate study, Lababidi et al., further examined the success CASDs had in pul-
monary drug delivery by which azithromycin and ciprofloxacin were spray dried with
L-leucine and n-acetyl cysteine (NAC), an amino acid derivative and known mucolytic [129].
Mucolytics are used in combination with antibiotics to dissolve thick mucus found in the CF
lung [157,158]. When mucolytics, such as NAC, are used as CASDs coformers, the formula-
tion benefit becomes two-fold, creating a more effective treatment with better formulation
characteristics. As mentioned before, the addition of L-leucine is aimed at reducing particle
cohesion and increasing aerosolisation properties. However, in the study conducted by
Lababidi et al., the main aim of adding NAC was to the formulation was to dissolve mucus,
enhancing antibiotic effect against the bacteria. The authors showed that azithromycin/n-
acetyl cysteine combination reduced P. aeruginosa biofilm by 25% at a concentration of
0.3 µm/mL compared to azithromycin and n-acetyl cysteine alone.
Forming amorphous dispersions composed of antimicrobials through complex for-
mation with metal cations has been explored as a method for enhancing formulation
characteristics of inhaled antimicrobials. Lamy et al., produced inhalable dry powder
microparticles of ciprofloxacin, complexed with calcium or copper ions (Cip-Ca; Cip-Cu),
through spray drying [159,160]. The resulting powders were amorphous, and both cal-
cium and copper formulations showed similar shell-like morphology, characteristic of
spray dried materials, and similar in vitro solution properties. When comparing phar-
macokinetics in vivo, both formulations showed enhanced lung retention compared to
the ciprofloxacin control, suggesting that forming metal counterion complexes can reduce
the rate of transcellular diffusion from the lung fluid. It was also seen that the ratio of
ciprofloxacin in epithelial lining fluid to plasma was five times greater for the Cip-Cu
than Cip-Ca formulations. The authors linked this with the strength of complex which
had formed, corresponding to: The enhanced stability of the Cip-Cu, a slower rate of
absorption into plasma and longer elimination half-life. Thus, antibiotic lung retention can
be controlled depending on the metal ion selected, leading to an optimised concentration
in lung fluid.
The influence of metal salts on the inhalation properties of levofloxacin has also been
analysed. Barazesh et al., cospray dried levofloxacin with four metal chloride salts with and
without leucine [161]. Sodium (Na) and potassium (K) monovalent salts were compared
with magnesium (Mg) and calcium (Ca) divalent salts. When measuring aerosol properties,
most effects was seen for formulations containing the highest measured percentage of
metal ion (i.e., 20% w/w). It was also observed that the addition of divalent salts reduced
the FPF of formulations and caused higher water retention post spray drying. The authors
concluded that the highly hygroscopic divalent metal salts are likely to uptake more
water, leading to local crystallisation and particle aggregation. Monovalent salts at 20%
w/w showed a higher FPF compared to lower concentrations. With respect to leucine
formulations, FPF was significantly higher, corresponding to the characteristic corrugated
effect seen when spray drying with leucine.
9. The Design of Carrier Free Formulations Using Cocrystals
The formulation of carrier free dry powders can be achieved by a variety of meth-
ods. These include the formation of salts, such as the generation of a sildenafil-citrate
salt [92], forming complexes with cationic groups, such as the generation of indomethacin
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and polylysine microparticles [89], and forming CASDs, such as with ciprofloxacin and
colistin [101]. Another route being investigated is the generation of cocrystals and seems
to be a promising method of improving physicochemical properties if other methods are
not suitable. For example, with the formation of salts, if the API is neutral, and therefore,
does not contain an acidic or basic group that can be ionised, salts cannot be practically
formed [162]. Cocrystallisation may also be seen as a more desirable method of physico-
chemical enhancement than others, for example, CASDs, due to enhanced physical and
chemical stability [163].
Pharmaceutical cocrystals are multicomponent crystals formed between an API and
pharmaceutically acceptable coformer. API and coformer exist in a fixed stoichiometric ratio
held together through [164] non-covalent and non-ionic interactions. These interactions are
intermolecular in nature and include hydrogen bonding, halogen bonding, π-π stacking
and van der Waal forces [165]. Hydrogen bonds are considered the ‘key interaction’ for
cocrystallisation, due to their strength, directionality and being commonly found in organic
molecules [166]. Therefore, cocrystals are distinct from polymorphs, due to multiple
components, and salts, due to lack of ionisation, and CASDs, due to their crystalline nature.
The formulation of APIs as cocrystals is regarded as a physical modification to improve
physicochemical properties, which maintains the API pharmacodynamic profile [167].
Since the cocrystal is a unique crystalline entity, it has unique physical properties, including
solubility, dissolution, flowability and stability. In general, coformers are chosen based
on molecular compatibility, as well as possession of desired physical property change.
For example, to improve an API’s solubility, one would choose a coformer with compatible
functional groups, as well as high solubility [168].
Cocrystallisation is currently attracting considerable interest, due to the improved
physicochemical properties that can be introduced to the API [169,170]. For example,
cocrystals of meloxicam–succinic acid were combined with PEG 4000 to enhance aqueous
solubility [171]. Cocrystals have largely been studied with a focus on improving oral drug
delivery, and it is only recently that studies have begun to explore how cocrystals can be
used for other administration routes, including pulmonary drug delivery. It is important to
focus on all changes to API physical properties rather than flowability and dispersion alone.
For example, altering solubility and dissolution will influence retention and epithelium
wall permeation which will determine either a local or systemic effect. Selecting the correct
coformer can increase aerosolisation properties, as well as maintaining the balance between
API retention in the lung and API clearance through various mechanisms [172].
M Karashima et al., produced micronised powder formulations of itraconazole for in-
halation using cocrystallisation and jet-milling [163]. These cocrystal formulations showed
superior aerodynamics compared with itraconazole control put through the same process-
ing and amorphous itraconazole spray dried with mannitol corresponding with reduced
particle size. Also tested were the intrinsic dissolution rates of cocrystal formulations
compared to itraconazole and amorphous itraconazole in mock lung surfactant. After 1 h,
the dissolved concentration of itraconazole from cocrystal formulations were between 5 and
10 times higher than itraconazole and the amorphous form. The authors reported higher
plasma concentrations (Cmax) compared to itraconazole and the amorphous form of itra-
conazole. Comparing this finding with intrinsic dissolution data, supports the conclusion
that the extent of dissolution in the lungs influences the extent of systemic partitioning.
Alhalaweh et al., produced several inhalable powders of theophylline through cocrys-
tallisation with nicotinamide, urea and saccharin [173]. These were compared against
theophylline control, but also against cocrystals formulated with lactose carrier. The au-
thors comment that cocrystal formulations showed more favourable aerosolisation with
less API loss, due to impaction. However, not all cocrystal formulations were better
aerodynamically compared to the control. This highlights the unpredictable nature of
coformer selection in cocrystal formation and the importance of considering all aspects
of physical property changes. Tanaka et al., produced a theophylline:oxalic acid cocrystal
through a combination of spray and freeze drying [174]. When compared to the control,
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the resulting formulation showed resistance to hygroscopicity and polymorphic transition
whilst maintaining good pulmonary delivery. The authors attribute this stability to the low
recorded energy state and close intermolecular interactions within the cocrystal.
API solution properties are a key component to determining API destination following
inhalation. One study investigated how the properties of 5-fluorouracil differ from three dif-
ferent cocrystals created with gentisic acid (FUGA), 4,5 dihydroxybenzoic acid (FUBA) and
4-aminopyridine (FUPN). This study determined that the intrinsic dissolution of all three
cocrystals were increased compared to pure 5-fluorouracil in both pHs of 1.2 and 6.8, with
the largest difference being between 5-fluoruracil and FUPN. 5-fluorouracil had an intrinsic
dissolution rate (IDR) of 0.12 mg cm−2/s in pH 1.2 and 0.18 cm−2/s in pH 6.8, whereas
FUPN had an IDR of 0.7 mg cm−2/s in pH 1.2 and 0.92 mg cm−2/s in pH 6.8, showing
more rapid dissolution from the cocrystal forms of 5-fluoruracil than the pure API [175].
Increased dissolution has also been observed in three diacerein cocrystals with isonicoti-
namide, nicotinamide and theophylline (DA-ISO), (DA-NIC) and (DA-THE). Diacerein had
an IDR of 0.065 mg cm−2/min compared to 0.216 mg cm−2/min, 0.284 mg cm−2/min and
0.137 mg cm−2/min for DA-ISO, DA-NIC and DA-THE, respectively. This again shows
that each cocrystal had a higher IDR value than the pure API molecule, suggesting a faster
rate of dissolution [176].
Another study demonstrated the effects that cocrystals have on the pharmacokinetic
profile of a drug. Daidzein and three cocrystals, with isonicotinamide (DIS), cytosine
(DCYT) and theobromine (DTB) as the coformers, were compared. It was found that all
three cocrystals had higher Cmax values, than daidzein (870.5 ng/mL), with DIS pos-
sessing the highest Cmax (1848.7 ng/mL). In addition, the time taken to reach the Cmax
(Tmax) values for each cocrystal was 3 h compared to 4 h for pure daidzein [177]. Table 8
summarises a variety of cocrystal formulations, the method of manufacture used and
the difference between API and coformer molecular weight. Shown is that cocrystallisation
applied to a great variety of different APIs produced through a wide range of different
production methods. Of note are the studies which use methods applicable for producing
inhalable dry powders, such as spray drying, spray freeze drying and jet milling. It also
gives an example of the wide variety of successful coformers available for cocrystallisation,
suggesting a great variety in physical property variations even for the same API. Examples
of drug:drug cocrystals are listed to show the possibility of creating synergistic therapies
through a single phase crystalline powder, i.e., cocrystals. As shown in Table 8 and Figure 4,
all coformers have molecular weights lower than alpha-lactose monohydrate (342.3 g/mol)
and either much smaller or similar molecular weight to the API. This demonstrates how
formulations containing coformers take up less volume in comparison to carrier-based
delivery systems. As discussed earlier, the volume which lactose particles take up in formu-
lations restricts the quantity of API that can be practically delivered. By avoiding the use
of carrier particles, through coformer based methods, greater amounts of API particles can
be formulated within a DPI device, possibly increasing the dose of API per actuation.
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Table 8. Cocrystalline APIs, their coformers, technology used and molecular weights.








Levofloxacin Metacetamol Grinding and heating 361.37 151.16 [178]
Pyrazinamide 3-Hydroxy benzoic acid Slow evaporation and neat grinding 123.11 138.12 [179]
Dapsone Caffeine Slow evaporation, liquid-assistedgrinding, spray drying 248.30 194.19 [180]
Nitrofurantoin Melamine Slow evaporation 238.16 126.12 [181]
Telaprevir 4-aminosalicylic acid Ball milling 679.85 153.14 [182]
Trimethoprim Glutarimide Slow evaporation 290.32 113.11 [183]
Telmisartan











Adefovir Stearic acid Antisolvent precipitation 273.19 284.50 [187]
Acyclovir Fumaric acid Liquid-assisted grinding 225.20 116.07 [188]
Meloxicam Aspirin Solution, slurry and solvent drop methods 351.40 180.16 [189]
Theophylline Oxalic acid Spray freeze drying 180.16 90.03 [174]
Niclosamide Nicotinamide Spray drying 327.12 122.12 [190]
Lomefloxacin
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Figure 4. A scatter graph of the data from Table 8 comparing the molecular weights of the APIs and
their coformers.
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10. Conclusions
Coamorphous solid dispersions and cocrystals are attractive physical structures that
have been used to improve the physicochemical properties of inhaled APIs to target in-
fections and lung cancer. When developing pharmaceutical cocrystals/coamorphous for
inhalation, careful selection of the coformer should be followed to improve the efficacy to
deliver drugs to the lungs. It is likely that by creating cocrystals/coamorphous dispersions,
the need for carrier particles in DPIs can be eliminated, and therefore, a greater amount
of the API can be delivered. This would result in an increased dose in each inhalation,
allowing lower potency drugs that require higher doses to be formulated for inhalation.
It is important to understand the complexities of pulmonary drug delivery when consid-
ering the formulation of drugs for inhalation to ensure the drug particles have adequate
aerosolization properties. This is necessary to ensure the particles can reach deep into
the lungs at the site of action, without being aggregated or immediately exhaled from
the lungs. It is important to consider all steps throughout drug development process,
including the excipients that are used and the devices to administer the drug, because some
of the devices have shown clear advantages when it comes to overcoming the challenges
with formulating inhaled APIs. The complexity of diseases imposes greater challenges
demanding more studies to optimise particles properties for better deposition. Ultimately,
it is crucial to match the properties of the particles to the desired site of action, such as
the case when targeting bacterial biofilms and cancer.
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